(Q47630188)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Richard Harrop

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Jackie de Belin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Michelle Kelleher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Gemma Bolton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Stuart Naylor

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

William H Shingler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

13 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

2283-2294

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-012-1302-9

4 February 2020

exact match

0 references

cites work

A 72 kD trophoblast glycoprotein defined by a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Immunohistological distribution of 5T4 antigen in normal and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Impact of tumour volume on the potential efficacy of therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Iron sequestration and anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Iron Deficiency and Erythropoiesis: New Diagnostic Approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Inflammatory mediators hold the key to dendritic cell suppression and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

A methodological framework to enhance the clinical success of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1302-9

10.1007/S00262-012-1302-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22692758%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference